Press Room

Article / Feb 24, 2008

An International Company of Portugal acquires a TaiZhou Pharmaceutical Company

TaiZhou Commercial Daily, 24 February 2008

An International Company of Portugal acquires a TaiZhou Pharmaceutical Company | Hovione

People from Pharmaceutical Business indicate this acquisition will assist to upgrade the Pharmaceutical business in TaiZhou.

In 22nd February 2008 afternoon, Hovione FarmaCiencia SA completed the acquisition of the ZheJiang HiSyn Pharmaceutical Company Limited. This is the first Equity Joint Venture in Pharmaceutical field in ZheJiang Province Chemical and Medical Materials Base LinHai Park, showing a positive trend.

“We have good expectation on the API manufacturers in TaiZhou, the cost and human resources advantage of the China API companies combined with our technical and marketing advantage will be a winning proposition. Our joint venture will produce a huge chemical reaction.” said by the CEO of Hovione, Mr. Guy Villax with smile.

“Hovione” is a Portugal international company with 50 years of history, the main products are API manufacturing, and her products have higher market shares in EEC, USA and Japan. Hovione used 150 million to acquire 75% shares of HiSyn this time, and indicated that the management team will be kept unchanged after the acquisition and the increased investment will be to support HiSyn to meet the international standards.
The development history of the TaiZhou pharmaceutical business is more than 40 years, is one of the key product line in our city. Since, the business structure; creative abilities; environment protection; utilities saving and the basic facilities investment of the pharmaceutical companies in our city are rather poor. So that, the development plan of the Taizhou pharmaceutical business (2007-2012) was indicated that until 2012 we will build up a pharmaceutical park with higher international competition, and emphasize to develop five big products during the period, starting the “139” project.

As per people come from the pharmaceutical business, the entrance of the international pharmaceutical companies in TaiZhou, will provide direct, positive and incentive effect on the upgrading of the pharmaceutical business in TaiZhou. And as per the Administrative Committee, they will incent the current exiting companies to co-operate with the group companies both from China and international. Now, there have several companies are under negotiation with the foreign companies.

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024